In fact, small molecule agonists of hnRNPA2B1, such as pac5, have already been developed and shown benefits in treating HBV and SARS-CoV-2 omicron infections.525 Applying these developments to cancer therapy is a promising direction for future exploration. Here, HNRNPA2B1 is linked to cancer.